|
|
Press Releases
| All 2008 Releases |
|---|
 |
Osiris Therapeutics to Present at 27th Annual J.P. Morgan Healthcare Conference
12-22-08
10.1 KB
|
| |
COLUMBIA, Md., Dec 22, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is ...
|
|
Osiris Receives Approval for Prochymal Expanded Access Program in Canada
12-05-08
13.6 KB
|
| |
COLUMBIA, Md., Dec 05, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced it has received
approval from Health Canada to initiate a pediatric expanded access
treatment program for Prochymal, making the investigational stem cell
product more readily available to children with life-threatening Graf...
|
|
Osiris Completes Enrollment in First Worldwide Phase III StemCell Trial
12-04-08
15.2 KB
|
| |
COLUMBIA, Md., Dec 04, 2008 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) announced today that it has
completed patient enrollment in its Phase III pivotal trial evaluating
Prochymal for the treatment of steroid-refractory acute Graft versus
Host Disease (GvHD), a life threatening complication of bone ma...
|
|
Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health Care Conference
11-26-08
10.2 KB
|
| |
COLUMBIA, Md., Nov 26, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is ...
|
|
Osiris Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11-06-08
9.7 KB
|
| |
COLUMBIA, Md., Nov 06, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at ...
|
|
Osiris Therapeutics Reports Third Quarter 2008 Financial Results
11-04-08
18.1 KB
|
| |
COLUMBIA, Md., Nov 04, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the third quarter of 2008.
Highlights and Recent Deve...
|
|
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
11-04-08
18.5 KB
|
| |
CAMBRIDGE, Mass. & COLUMBIA, Md., Nov 04, 2008 (BUSINESS WIRE) -- Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to t...
|
|
Osiris Announces Third Quarter 2008 Financial Results Conference Call
10-31-08
12.0 KB
|
| |
COLUMBIA, Md., Oct 31, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leader in stem cell therapeutics, announced today that it will report its financial results for the quarter ended September 30, 2008, on Tuesday, November 4, 2008. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Richard Hunt, Chief Financi...
|
|
Osiris Therapeutics to Present at the 7th Annual BIO Investor Forum
10-27-08
9.7 KB
|
| |
COLUMBIA, Md., Oct 27, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at ...
|
|
Osiris Therapeutics to Present at the JMP Securities Healthcare Focus Conference
10-02-08
9.7 KB
|
| |
COLUMBIA, Md., Oct 02, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
